Intervenn Biosciences was co-founded by faculty members at Stanford University and University of California, Berkeley.

Intervenn Biosciences, a US-based precision medicine technology developer co-founded by Stanford University and University of California, Berkeley faculty, has closed a $201m series C round. The round was co-led by telecoms firm SoftBank, health system Heritage Provider Network, Irving Investors and Highside Capital Management. It was filled out by Amplify Partners, Anzu Partners, Genoa Ventures…

The rest of this content is only accessible to University Venturing: News, Data, and Events - Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.